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ABSTRACT
Helicobacter pylori is the most common infection causing gastrointestinal diseases in the developing countries. It causes oxidative damage to gastric 
mucosal cells thereby altering the epithelial proliferation of these cells. With proton pump inhibitors and antibiotics being the mainstay in the 
management of symptoms, preclinical and clinical research is making inroads with novel therapeutic innovations to target the bacterium with the 
help of antioxidants. Hence, we report the first case of the treatment and eradication of H. pylori using L-glutamine, a sports medicine supplement 
with high antioxidant potential.
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INTRODUCTION
Helicobacter pylori is one of the most dreaded bacterial infection affecting 
more than 50% population globally. It causes many gastrointestinal 
diseases ranging from peptic ulcers, gastric ulcers, gastric carcinoma, 
and lymphomas. Various treatment regimens are used to treat this 
infection with proton pump inhibitors (PPI), antibiotics being the main 
stay in curing the disease. However, despite available drugs to treat the 
infections, there is increased prevalence of the infection in developing 
nations [1]. Hence, we report a case of 45-year-old male, diagnosed of 
H. pylori positive gastritis with reflux disease treated with L-glutamine 
in a tertiary care hospital in India.
CASE REPORT
Informed consent was taken from the patient. A 45-year-old male 
patient, business man by occupation, came with complaints of on and 
off abdominal pain, dyspepsia, bloating sensation in stomach after 
eating, heart burn, and epigastric tenderness after food intake. He had 
no symptoms of angina, and his vital examination was normal. Another 
system examination was also normal. 24-hrs monitoring of gastric PH 
was diagnostic of gastric esophageal reflux disease along with gastritis. 
Ultrasound abdomen was normal. Upper gastrointestinal endoscopy 
was suggestive of gastritis without any ulcer formation. Then, in view 
of H. pylori, infection patient was taken for biopsy and rapid urease 
test for H. pylori came positive. The patient was immediately started 
with triple drug therapy consisting of lansoprazole, amoxicillin, and 
clarithromycin for 14 days twice daily. There was no improvement in 
symptoms, and the whole treatment was again repeated for a course of 
14 days. After 2 courses of triple drug therapy, the patient was taken for 
second endoscopic biopsy to know the status of H. pylori infection. The 
patient was again positive for H. pylori. Then, the patient was started 
with oral L-glutamine supplement 1000 mg capsules twice daily for a 
period of 30 days. At the end of 30 days’ patient’s symptoms improved 
and a repeat biopsy of gastric tissue came negative for H. pylori. 
Hence, forth patient was advised diet changes and not to skip meals. 
He was also advised physical exercise and to avoid nonsteroidal anti-
inflammatory drugs and other drugs causing gastritis. On follow-up at 
6 months repeat biopsy again showed eradication of H. pylori infection 
and patient was completely cured and H. pylori eradicated.
DISCUSSION
H. pylori, affecting almost half of the population globally is highly 
prevalent in developing countries with an incidence of 90% compared to 
developed countries with 40% incidence [1]. It affects all ages and both 
men and women equally causing myriad of gastrointestinal problems 
ranging from peptic ulcer disease to gastric carcinomas. The effective 
treatment of H. pylori infection remains a challenge as the entire 
treatment depends on the availability of diagnostic procedures, choice 
of one detection method over other, cost of endoscopic procedures and 
also taking into consideration the age of the patient. Triple drug therapy 
remains the standard treatment measure offering good cure rates [1]. 
Various newer treatment options such as quadruple therapy, sequential 
therapy, and concomitant therapy have improved the cure rates in 
developing as well developed countries to a substantial amount. Rapid 
urease test of endoscopic stomach biopsies remains the most widely 
used method as it is inexpensive, rapid and cost effective with high 
specificity and sensitivity [1]. Triple therapy consists of lansoprazole 
30 mg, clarithromycin 500 mg, and amoxicillin 1g twice daily for 
14 days. In the case of allergy to penicillin’s, metronidazole is used [1]. 
A meta-analysis revealed triple therapy had 6-10% high eradication 
rates when compared to PPI when used alone [2]. Lactoferrin in 
combination with triple therapy is used to reduce the side effect of 
the drugs. In the case of high resistance to clarithromycin, quadruple 
therapy consisting of PPI, bismuth subsalicylate (525 mg, × 4 daily), 
metronidazole (250 mg × 4 daily), and tetracycline (500 mg, × 4 daily), 
for 10-14 d is used [3]. Sequential therapy involves the use of PPI plus 
amoxicillin for first 5 days followed by metronidazole/clarithromycin 
for next 5 days. A meta-analysis showed sequential therapy was better 
than 7-day triple drug therapy, but there was no significant difference 
when compared with 14-day triple therapy [4]. In the case of resistance 
of clarithromycin more than 20%, concomitant therapy consisting of 
three antibiotics (metronidazole, clarithromycin, and amoxicillin) and 
a PPI for 10 days is used and is found to be effective and well tolerated 
compared to triple therapy [5].
Oxidative stress has been implicated in the pathogenesis of H. pylori 
infections and increased oxidative damage by H. pylori is responsible 
for epithelial injury, altered epithelial proliferation, and increased 
apoptosis [6]. Furthermore, it has been found out that there is an 
accumulation of ammonia in the gastric tissues which leads to gastric 
mucosal damage [7]. H. pylori has specificity for gastric epithelium 
and is enhanced by oxidative damage [8]. L-glutamine commonly 
used in sports medicine for muscle recovery is a non-essential amino 
acid and has gained medical importance because of its antioxidant 
properties [9]. The antioxidant properties of L -glutamine have been 
claimed to be useful in the treatment of peptic ulcer disease in animal 
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studies as well in very few human studies. Only a few animal studies 
have been conducted so far to investigate the role L-glutamine in the 
treatment of H. pylori infections and it was found to be positive, yet 
human trials have not been done in large scale [10]. As evidence says, 
glutamine helps in reducing the accumulation of ammonia in gastric 
tissue and cells as well it helps in reducing the oxidative free radicals 
in gastric tissue thereby controlling the changes induced by H. pylori 
infection in gastric epithelial cells [9]. Our case is the first one to be 
reported so far in world literature where L-glutamine has been used 
in the treatment of gastritis with reflux disease in a male patient after 
failure in eradicating helicobacter infection by conventional methods. 
In our case, the patient was given a 14-day course of triple drug therapy 
twice in a month and after the failure of the treatment was started on 
L-glutamine supplementation for 30 days. This novel treatment with 
L-glutamine resulted in complete eradication of the bacterial infection 
with negative rapid urease test of the biopsy samples. The patient 
was followed up for 6 months, and he was normal, and there was no 
recurrence of gastric symptoms. There were no adverse effects noted 
during the treatment and patient was very much agile and active.
CONCLUSION
Further clinical trials can be done using L-glutamine in H. pylori infected 
patients and efficacy and safety can be evaluated in comparison with 
conventional treatment methods. This was the first case report in the 
world, on using L-glutamine in the treatment of gastritis with reflux 
disease due to H. pylori. Hence, antioxidative properties of L-glutamine can 
be of great help in revolutionizing the management of H. pylori infections.
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